Bio Products Laboratory

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Bio Products Laboratory sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 8 completed later-stage tilt top decile by trial count

Bio Products Laboratory: 9 sponsored US clinical trials, none currently recruiting.

Bio Products Laboratory sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 7 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Immunodeficiency With Hyper-IgM, with 1 trials.

Top-decile sponsor footprint

Bio Products Laboratory ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

COMPLETED

Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery

NCT03161626
COMPLETED Phase 2

Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects

NCT03264157
COMPLETED Phase 3

Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases

NCT01884311
COMPLETED Phase 3

Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases

NCT01963143
COMPLETED Phase 4

A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency

NCT01289847
TERMINATED Phase 3

Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery

NCT01086852
COMPLETED Phase 3

A Study Investigating Treatment Factor X in People With Factor X Deficiency

NCT00930176
COMPLETED Phase 3

A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT00504075
COMPLETED Phase 3

Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.

NCT00278954

Phase Distribution

PhaseTrial count
Phase 2 1
Phase 3 6
Phase 4 1

Therapeutic Areas

Immunodeficiency With Hyper-IgM 1
X-linked Hypogammaglobulinemia 1
Common Variable Hypogammaglobulinemia 1
Wiskott-Aldrich Syndrome 1
Primary Immunodeficiency 1
Hypogammaglobulinemia 1

How the Bio Products Laboratory archive is shaped

9 indexed studies, none listed as recruiting (0% open); 8 completed (89%).

Phase mix: 7 late (III/IV) vs 1 early (I/II) (later-stage heavy).

Top condition: Immunodeficiency With Hyper-IgM (1 trial), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Bio Products Laboratory: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Bio Products Laboratory sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Bio Products Laboratory4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Bio Products Laboratory sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Bio Products Laboratory sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Bio Products Laboratory page

9 registered trials is a research-attention snapshot, not an endorsement of Bio Products Laboratory or any single study.

  • None of Bio Products Laboratory's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Immunodeficiency With Hyper-IgM is the condition Bio Products Laboratory studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Immunodeficiency With Hyper-IgM trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Bio Products Laboratory pipeline card: 9 registered trials from official public datasets.Report a data error.